Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
1.370
+0.010 (0.74%)
Apr 25, 2025, 4:00 PM EDT - Market closed
SONN Employees
Sonnet BioTherapeutics Holdings had 13 employees as of September 30, 2024. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$76,923
Profits / Employee
-$725,341
Market Cap
4.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SONN News
- 11 days ago - Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewsWire
- 23 days ago - Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose - GlobeNewsWire
- 26 days ago - Sonnet Announces Release of Corporate Update Video - GlobeNewsWire
- 26 days ago - Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - GlobeNewsWire
- 4 weeks ago - Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas - GlobeNewsWire
- 5 weeks ago - Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 2 months ago - Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - GlobeNewsWire